Loss of vision has a profound impact on quality of life and impairs one's ability to function independently. Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (ARMD) are two of the leading causes of non-congenital blindness (RP: Heckenlively, Boughman, & Friedman,
1988; Pagon,
1988; ARMD: Klein, Klein, & Linton,
1992; VanNewkirk et al.,
2000; Vingerling et al.,
1995). RP affects between 1/3000 and 1/5000 individuals (Pagon,
1988), and ARMD accounts for the majority of permanent loss of vision in people over the age of 50 (Klein et al.,
1992; VanNewkirk et al.,
2000; Vingerling et al.,
1995). These degenerative disorders primarily affect the photoreceptors in the retina while leaving the rest of the retina and visual pathway relatively intact (Kim et al.,
2002; Santos et al.,
1997; Stone, Barlow, Humayun, de Juan, & Milam,
1992). Electrical stimulation of the remaining retinal circuitry has been explored as a possible strategy for the creation of a visual prosthesis for blind patients, and clinical trials have yielded promising results (Caspi et al.,
2009; Humayun et al.,
1996,
2003; Rizzo, Wyatt, Loewenstein, Kelly, & Shire,
2003; Yanai et al.,
2007) indicating that restoration of at least minimal vision with these implants is feasible. A retinal prosthesis would incorporate an external video camera for image acquisition, an image preprocessor converting the image to a suitable pattern of electrical stimulation, and finally the electrical stimulation array on the retina itself. For an overview of the current state of the art, see, e.g., Chader, Weiland, and Humayun (
2009), Dowling (
2008), Sachs and Gabel (
2004), and Weiland, Liu, and Humayun (
2005).